ArticleThe Journal of pathology2022
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8
Open access · greenAbstract read
In one paragraph
Article in The Journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Deciphering the Pleiotropic Role ofCells · 2026Article
- AI-based quantification of tumor-infiltrating lymphocytes with integrative transcriptomics in ovarian clear cell carcinoma: JGOG3025-TR1/A1 study.Cancer immunology, immunotherapy : CII · 2026Article
- Current Developments of CAR-T and CAR-NK Cell Therapies for Ovarian Cancer.Stem cell reviews and reports · 2026Review
- Bacillus Calmette-Guerin induces CD8+ T cell infiltration and suppresses tumor progression in microsatellite stable colorectal cancer by downregulating ARID1A.Cancer gene therapy · 2025Article
- Context is key: how diagnostic and prognostic markers are reshaping gynecologic pathology.The journal of pathology. Clinical research · 2025Review
- ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Cystathionine gamma-lyase-mediated hypoxia inducible factor 1-alpha expression drives clear cell ovarian cancer progression.The Journal of pathology · 2025Article
- High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target.Cancer research communications · 2025Article
- Clinicopathological characterization of Switch/Sucrose-non-fermentable (Swi/Snf) complex (ARID1A, SMARCA2, SMARCA4)-deficient endocervical adenocarcinoma.Cancer cell international · 2025Article
- Somatic PTEN and ARID1A loss and endometriosis disease burden: a longitudinal study.Human reproduction (Oxford, England) · 2025Article
- Molecular Pathology of Ovarian Endometrioid Carcinoma: A Review.Oncology research · 2025Review
- SOX17 expression in ovarian clear cell carcinoma.Journal of ovarian research · 2024Article
- Genome-Wide CRISPR Screen Identifies KEAP1 Perturbation as a Vulnerability of ARID1A-Deficient Cells.Cancers · 2024Article
- ARID1A in Gynecologic Precancers and Cancers.Reproductive sciences (Thousand Oaks, Calif.) · 2024Review
- Mesonephric-type adenocarcinomas of the ovary: prevalence, diagnostic reproducibility, outcome, and value of PAX2.The journal of pathology. Clinical research · 2024Article
- Genomic alterations in ovarian endometriosis and subsequently diagnosed ovarian carcinoma.Human reproduction (Oxford, England) · 2024Article
- Research progress in endometriosis-associated ovarian cancer.Frontiers in oncology · 2024Review
- Review
- The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Prognostic and immune infiltration significance of ARID1A in TCGA molecular subtypes of gastric adenocarcinoma.Cancer medicine · 2023Article
Corrections and comments
- Commented on by
Authors and funding
82 authors at 20 institutions in 8 countries.
Karolin Heinze *Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.ORCID 0000-0002-5066-3780
Tayyebeh M Nazeran *University of British Columbia, Vancouver General Hospital, and BC Cancer. British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, Canada.
Sandra LeeDepartment of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada.
Pauline KrämerDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.
Evan S CairnsDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.
Derek S ChiuUniversity of British Columbia, Vancouver General Hospital, and BC Cancer. British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, Canada.
Samuel Cy LeungUniversity of British Columbia, Vancouver General Hospital, and BC Cancer. British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, Canada.
Eun Young KangDepartment of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada.
Nicola S MeagherUniversity of New South Wales, Adult Cancer Program, Lowy Cancer Research Centre, Sydney, Australia.
Catherine J KennedyThe University of Sydney, Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, Australia.
Jessica BorosThe University of Sydney, Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, Australia.
Friedrich KommossMedizin Campus Bodensee, Institute of Pathology, Friedrichshafen, Germany.
Hans-Walter VollertDepartment of Gynecology and Obstetrics, Medizin Campus Bodensee, Friedrichshafen, Germany.
Florian HeitzDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.
Andreas du BoisDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.
Philipp HarterDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.
Marcel GrubeDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.
Bernhard KraemerDepartment of Women's Health, University Hospital Tübingen, Tübingen, Germany.
Annette StaeblerUniversity Hospital Tübingen, Institute of Pathology and Neuropathology, Tübingen, Germany.
Felix Kf KommossUniversity Hospital Heidelberg, Institute of Pathology, Heidelberg, Germany.
Sabine HeubleinDepartment of Obstetrics and Gynecology, University Hospital Heidelberg and National Center for Tumor Diseases, Heidelberg, Germany.
Hans-Peter SinnUniversity Hospital Heidelberg, Institute of Pathology, Heidelberg, Germany.
Naveena SinghDepartment of Pathology, Barts Health National Health Service Trust, London, UK.
Angela LaslavicDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Esther ElishaevDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Alex OlawaiyeDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Kirsten MoysichDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
Francesmary ModugnoDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Raghwa SharmaWestmead Hospital, Tissue Pathology and Diagnostic Oncology, Sydney, Australia.
Alison H BrandDepartment of Gynaecological Oncology, Westmead Hospital, Sydney, Australia.
Paul R HarnettDepartment of Gynaecological Oncology, Westmead Hospital, Sydney, Australia.
Anna DeFazioThe University of Sydney, Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, Australia.
Renée T FortnerDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jan LubinskiDepartment of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland.
Marcin LenerDepartment of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland.
Aleksandra Tołoczko-GrabarekDepartment of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland.
Cezary CybulskiDepartment of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland.
Helena GronwaldDepartment of Propaedeutics, Physical Diagnostics and Dental Physiotherapy, Pomeranian Medical University, Szczecin, Poland.
Jacek GronwaldDepartment of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland.
Penny CoulsonDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Mona A El-BahrawyDepartment of Metabolism, Digestion and Reproduction, Hammersmith Hospital, Imperial College London, London, UK.
Michael E JonesDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Minouk J SchoemakerDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Anthony J SwerdlowDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Kylie L GorringeSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.
Ian CampbellSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.ORCID 0000-0002-7773-4155
Linda CookDivision of Epidemiology and Biostatistics, The University of New Mexico, Albuquerque, NM, USA.
Simon A GaytherCedars-Sinai Medical Center, Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Los Angeles, CA, USA.
Michael E CarneyDepartment of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.
Yurii B ShvetsovUniversity of Hawaii Cancer Center, Epidemiology Program, Honolulu, HI, USA.
Brenda Y HernandezUniversity of Hawaii Cancer Center, Epidemiology Program, Honolulu, HI, USA.
Lynne R WilkensUniversity of Hawaii Cancer Center, Epidemiology Program, Honolulu, HI, USA.
Marc T GoodmanCedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Los Angeles, CA, USA.
Constantina MateoiuDepartment of Obstetrics and Gynecology, Sahlgrenska Academy at Gothenburg University, Sahlgrenska Center for Cancer Research, Gothenburg, Sweden.
Anna LinderDepartment of Obstetrics and Gynecology, Sahlgrenska Academy at Gothenburg University, Sahlgrenska Center for Cancer Research, Gothenburg, Sweden.
Karin SundfeldtDepartment of Obstetrics and Gynecology, Sahlgrenska Academy at Gothenburg University, Sahlgrenska Center for Cancer Research, Gothenburg, Sweden.
Linda E KelemenHollings Cancer Center and Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
Aleksandra Gentry-MaharajUniversity College London, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK.
Martin WidschwendterUniversity of Innsbruck, EUTOPS Institute, Innsbruck, Austria.
Usha MenonUniversity College London, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK.
Kelly L BoltonDepartment of Hematology and Oncology, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Jennifer AlsopCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
Mitul ShahDepartment of Histopathology, Addenbrookes Hospital, Cambridge, UK.
Mercedes Jimenez-LinanDepartment of Histopathology, Addenbrookes Hospital, Cambridge, UK.
Paul Dp PharoahCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
James D BrentonUniversity of Cambridge, Cancer Research UK Cambridge Institute, Cambridge, UK.
Kara L Cushing-HaugenProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Holly R HarrisProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jennifer A DohertyHuntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA.
Blake GilksUniversity of British Columbia, Vancouver General Hospital, and BC Cancer. British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, Canada.ORCID 0000-0001-7889-8250
Prafull GhatageDepartment of Oncology, Division of Gynecologic Oncology, University of Calgary, Calgary, Canada.
David G HuntsmanDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.
Gregg S NelsonDepartment of Oncology, Division of Gynecologic Oncology, University of Calgary, Calgary, Canada.
Anna V TinkerUniversity of British Columbia, Vancouver General Hospital, and BC Cancer. British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, Canada.
Cheng-Han LeeUniversity of Alberta, Department of Laboratory Medicine and Pathology, Edmonton, Canada.
Ellen L GoodeDivision of Epidemiology, Department of Health Science Research, Mayo Clinic, Rochester, MN, USA.
Brad H NelsonTrev & Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, Canada.
Susan J RamusUniversity of New South Wales, Adult Cancer Program, Lowy Cancer Research Centre, Sydney, Australia.
Stefan KommossDepartment of Women's Health, University Hospital Tübingen, Tübingen, Germany.
Aline TalhoukDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.
Martin KöbelDepartment of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada.ORCID 0000-0002-6615-2037
Michael S AnglesioDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.ORCID 0000-0003-1639-5003
BC Cancer Agency · CAInternational Hereditary Cancer Center · PLThe University of Sydney · AUUniversity of Calgary · CAHeidelberg University · DEInstitute of Cancer Research · GBUniversity of Hawaiʻi at Mānoa · USUniversity of Pittsburgh · USKliniken Essen-Mitte · DESahlgrenska University Hospital · SEUniversity Children's Hospital Tübingen · DEUniversity of British Columbia · CAUniversity of Cambridge · GBAddenbrooke's Hospital · GBCancer Institute of New South Wales · AUCedars-Sinai Medical Center · USFred Hutch Cancer Center · USMRC Clinical Trials Unit at UCL · GBThe University of Melbourne · AUGerman Cancer Research Center · DE
Funding
University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GERTRAUD MASKARINEC · 1996 to 2026
$56.2MWITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2MRelating Molecular Subgroups of Endometriosis-Associated Ovarian Cancers to Survival and RiskR01CA248288 · NCI · MAYO CLINIC ROCHESTER · PI Stacey J Winham · 2021 to 2026
$4.8MCOLLABORATIVE STUDY OF OVARIAN CANCER IN TWO RISK GROUPSR01CA058598 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GOODMAN, MARC T · 1993 to 2012
$4.6MEpidemiology of Ovarian Cancer:New HypothesesR01CA087538 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ROSSING, MARY ANNE · 2002 to 2006
$3.5MSteroid Hormone Genes and Ovarian Cancer RiskR01CA112523 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ROSSING, MARY ANNE · 2006 to 2010
$3.3MRegulatory T Cell Function in Ovarian CancerR01CA126841 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B. · 2009 to 2013
$3.0MInflammation and Ovarian CancerR01CA095023 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BUNKER, CLAREANN H. · 2003 to 2008
$2.7MEpidemiologic factors and survival by molecular subtypes of ovarian cancerR01CA168758 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DOHERTY, JENNIFER A., ROSSING, MARY ANNE · 2013 to 2016
$2.6MOVARIAN CANCER RISK AND SURVIVAL IN BRCA CARRIERSK07CA080668 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MODUGNO, FRANCESMARY · 2000 to 2005
$661kSURVEILLANCE EPIDEMIOLOGY AND END RESULTSN01CN025403 · CN · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROSS, RONALD K · 1992 to 1996
–Cancer Research UK 15601Cancer Research UK 22905NCI NIH HHS K07 CA080668NCI NIH HHS N01 CN025403NCI NIH HHS P30 CA071789NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA095023NCI NIH HHS R01 CA112523NCI NIH HHS R01 CA126841NCI NIH HHS R01 CA168758NCI NIH HHS R01 CA248288NCRR NIH HHS M01 RR000056
Abstract
ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumour suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory reports on its relationship to outcome, immune response, and correlation with clinicopathological features. We assembled a series of 1623 endometriosis-associated ovarian carcinomas, including 1078 endometrioid (ENOC) and 545 clear cell (CCOC) ovarian carcinomas, through combining resources of the Ovarian Tumor Tissue Analysis (OTTA) Consortium, the Canadian Ovarian Unified Experimental Resource (COEUR), local, and collaborative networks. Validated immunohistochemical surrogate assays for ARID1A mutations were applied to all samples. We investigated associations between ARID1A loss/mutation, clinical features, outcome, CD8
Indexed as
CarcinomaEndometriosisOvarian NeoplasmsBiomarkers, TumorBrain NeoplasmsCanadaCD8-Positive T-LymphocytesColorectal NeoplasmsDNA-Binding ProteinsFemaleHumansNeoplastic Syndromes, HereditaryNuclear ProteinsPrognosisTranscription FactorsARID1A protein, humanBiomarkers, TumorDNA-Binding ProteinsNuclear ProteinsTranscription FactorsARID1ACD8clear cell ovarian carcinomaDNA mismatch repairendometrioid ovarian carcinomaendometriosis-associated ovarian carcinomaimmunohistochemistryprognosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.